| |
 |
ARTICLES 
|
|
| A phase I trial on the ethics of phase I trials |
| EJ Emanuel |
|
JCO May 1 1995: 1049–1051.
[PDF]
|
 |
| Molecular markers and stem-cell transplants: are they made for each other? |
| RJ Schilder |
|
JCO May 1 1995: 1052–1054.
[PDF]
|
|
|
Attitudes and behaviors on physician-assisted death: a study of Michigan oncologists |
| |
DJ Doukas, D Waterhouse, DW Gorenflo, and J Seid |
| |
JCO May 1 1995: 1055–1061.
[Abstract]
[PDF]
|
|
|
Perceptions of cancer patients and their physicians involved in phase I trials [published erratum appears in J Clin Oncol 1995 Sep;13(9):2476] |
| |
C Daugherty, MJ Ratain, E Grochowski, C Stocking, E Kodish, R Mick, and M Siegler |
| |
JCO May 1 1995: 1062–1072.
[Abstract]
[PDF]
|
|
|
Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma |
| |
JE Hardingham, D Kotasek, RE Sage, LT Gooley, JX Mi, A Dobrovic, JE Norman, AE Bolton, and BM Dale |
| |
JCO May 1 1995: 1073–1079.
[Abstract]
[PDF]
|
|
|
Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report |
| |
NL Bartlett, SA Rosenberg, RT Hoppe, SL Hancock, and SJ Horning |
| |
JCO May 1 1995: 1080–1088.
[Abstract]
[PDF]
|
|
|
Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma |
| |
WP Vaughan, E Kris, J Vose, PJ Bierman, P Gwilt, and JO Armitage |
| |
JCO May 1 1995: 1089–1095.
[Abstract]
[PDF]
|
|
|
Allogeneic bone marrow transplantation for refractory and recurrent low- grade lymphoma: the case for aggressive management |
| |
KW van Besien, IF Khouri, SA Giralt, P McCarthy, R Mehra, BS Andersson, D Przepiorka, JL Gajewski, N Bellare, and R Nath |
| |
JCO May 1 1995: 1096–1102.
[Abstract]
[PDF]
|
|
|
Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation |
| |
A Bedi, CB Miller, JL Hanson, S Goodman, RF Ambinder, P Charache, RR Arthur, and RJ Jones |
| |
JCO May 1 1995: 1103–1109.
[Abstract]
[PDF]
|
|
|
Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer |
| |
FM Marincola, DE White, AP Wise, and SA Rosenberg |
| |
JCO May 1 1995: 1110–1122.
[Abstract]
[PDF]
|
|
|
Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer |
| |
CL Vogel, J Schoenfelder, I Shemano, DF Hayes, and RA Gams |
| |
JCO May 1 1995: 1123–1128.
[Abstract]
[PDF]
|
|
|
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer |
| |
K Leitzel, Y Teramoto, K Konrad, VM Chinchilli, G Volas, H Grossberg, H Harvey, L Demers, and A Lipton |
| |
JCO May 1 1995: 1129–1135.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer |
| |
MJ Kennedy, DK Armstrong, AM Huelskamp, K Ohly, BV Clarke, OM Colvin, LB Grochow, TL Chen, and NE Davidson |
| |
JCO May 1 1995: 1136–1143.
[Abstract]
[PDF]
|
|
|
Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up |
| |
CA Quiet, DJ Ferguson, RR Weichselbaum, and S Hellman |
| |
JCO May 1 1995: 1144–1151.
[Abstract]
[PDF]
|
|
|
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response |
| |
AD Seidman, BS Reichman, JP Crown, TJ Yao, V Currie, TB Hakes, CA Hudis, TA Gilewski, J Baselga, and P Forsythe |
| |
JCO May 1 1995: 1152–1159.
[Abstract]
[PDF]
|
|
|
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses |
| |
D Fennelly, J Schneider, D Spriggs, C Bengala, T Hakes, L Reich, R Barakat, J Curtin, MA Moore, and W Hoskins |
| |
JCO May 1 1995: 1160–1166.
[Abstract]
[PDF]
|
|
|
Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors |
| |
MA Cooper and LH Einhorn |
| |
JCO May 1 1995: 1167–1169.
[Abstract]
[PDF]
|
|
|
Late relapse of testicular cancer |
| |
J Baniel, RS Foster, R Gonin, JE Messemer, JP Donohue, and LH Einhorn |
| |
JCO May 1 1995: 1170–1176.
[Abstract]
[PDF]
|
|
|
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups |
| |
EW Steyerberg, HJ Keizer, SD Fossa, DT Sleijfer, GC Toner, H Schraffordt Koops, PF Mulders, JE Messemer, K Ney, and JP Donohue |
| |
JCO May 1 1995: 1177–1187.
[Abstract]
[PDF]
|
|
|
Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience |
| |
ME Gels, HJ Hoekstra, DT Sleijfer, J Marrink, HW de Bruijn, WM Molenaar, NJ Freling, JH Droste, and H Schraffordt Koops |
| |
JCO May 1 1995: 1188–1194.
[Abstract]
[PDF]
|
|
|
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications |
| |
RA Ghossein, HI Scher, WL Gerald, WK Kelly, T Curley, A Amsterdam, ZF Zhang, and J Rosai |
| |
JCO May 1 1995: 1195–1200.
[Abstract]
[PDF]
|
|
|
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial |
| |
CH Kohne, W Hiddemann, J Schuller, J Weiss, HP Lohrmann, U Schmitz-Hubner, H Bodenstein, C Schober, H Wilke, and J Grem |
| |
JCO May 1 1995: 1201–1208.
[Abstract]
[PDF]
|
|
|
Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial |
| |
EA Faylona, PJ Loehrer, R Ansari, AB Sandler, R Gonin, and LH Einhorn |
| |
JCO May 1 1995: 1209–1214.
[Abstract]
[PDF]
|
|
|
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients |
| |
U Lassen, K Osterlind, M Hansen, P Dombernowsky, B Bergman, and HH Hansen |
| |
JCO May 1 1995: 1215–1220.
[Abstract]
[PDF]
|
|
|
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party |
| |
M Paesmans, JP Sculier, P Libert, G Bureau, G Dabouis, J Thiriaux, J Michel, O Van Cutsem, R Sergysels, and P Mommen |
| |
JCO May 1 1995: 1221–1230.
[Abstract]
[PDF]
|
|
|
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial |
| |
G Somlo, JH Doroshow, A Lev-Ran, DC Ahn, L Hwang, JW Raschko, SJ Forman, KA Margolin, RJ Morgan, and LA Leong |
| |
JCO May 1 1995: 1231–1237.
[Abstract]
[PDF]
|
|
|
Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule |
| |
PC Adamson, J Bailey, J Pluda, DG Poplack, S Bauza, RF Murphy, R Yarchoan, and FM Balis |
| |
JCO May 1 1995: 1238–1241.
[Abstract]
[PDF]
|
|
|
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group |
| |
R Navari, D Gandara, P Hesketh, S Hall, J Mailliard, H Ritter, C Friedman, and D Fitts |
| |
JCO May 1 1995: 1242–1248.
[Abstract]
[PDF]
|
|
|
Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire |
| |
MJ Hjermstad, SD Fossa, K Bjordal, and S Kaasa |
| |
JCO May 1 1995: 1249–1254.
[Abstract]
[PDF]
|
|
|
Someone to live for: social well-being, parenthood status, and decision- making in oncology |
| |
SB Yellen and DF Cella |
| |
JCO May 1 1995: 1255–1264.
[Abstract]
[PDF]
|
|
|
Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung |
| |
GM Strauss, DJ Kwiatkowski, DH Harpole, TJ Lynch, AT Skarin, and DJ Sugarbaker |
| |
JCO May 1 1995: 1265–1279.
[Abstract]
[PDF]
|
|
| Autologous blood transfusions and prognosis in colorectal cancer surgery |
| OR Busch, WC Hop, RL Marquet, and J Jeekel |
|
JCO May 1 1995: 1280–1281.
[PDF]
|
|
| Intensified concomitant chemoradiotherapy for poor-prognosis head and neck cancer |
| I Alastuey |
|
JCO May 1 1995: 1281–1282.
[PDF]
|
|
| Treatment of elderly patients with antineoplastic chemotherapy |
| U Tirelli and S Monfardini |
|
JCO May 1 1995: 1282–1283.
[PDF]
|
|
| Application of the Cotswolds Criteria for the assessment of disease response in patients treated for Hodgkin's disease |
| DL Cooper and E Salloum |
|
JCO May 1 1995: 1283–1284.
[PDF]
|
|
| Complete remission in T-cell prolymphocytic leukemia with 2- chlorodeoxyadenosine |
| L Palomera, JM Domingo, JA Agullo, and M Soledad Romero |
|
JCO May 1 1995: 1284–1285.
[PDF]
|
|
